American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
Fresenius SE & Co. KGaA
$10.70
-0.93%
OTC: FSNUY · 15-min delayed
FSNUYOTC
1981Founded
About Fresenius SE & Co. KGaA
FRESENIUS SE S/ADR
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
OTC: FSNUY
$10.70
-0.93%
15-minute delayed · data by Polygon.io
Past year
$10.40
$22.45
52-week range
- Dividend yield
- 2.85%
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Trading 52% below its 52-week high.
- Pays a dividend yielding about 2.85% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Fresenius SE & Co. KGaA.
Write a review
Newsroom
News about Fresenius SE & Co. KGaA
Saudi Arabia Pharmaceutical CDMO Market Research Report 2025 Featuring Tabuk Manufacturing, Lifera, Saudi Bio, Fresenius Kabi, Hikma Pharma, Pfizer, Novartis
$9.48 Bn Medical Foods for Inborn Errors of Metabolism Market Opportunities and Strategies to 2034
Infusion Pumps Market to Soar at a CAGR of ~10% by 2032, Owing to the Advancements in Technology and Increased Demand in Healthcare | DelveInsight
Global Prefilled Syringes Market to Cross USD 28 Billion by 2032 | DelveInsight
Parenteral Nutrition Research Analysis 2024: A Global $13.6 Billion Market by 2029, Driven by Increased Utilization of Premixed PN Formulations and Growing Preference for Home Parenteral Nutrition
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - Report by Transparency Market Research, Inc.
News & sentiment via Polygon.io
Explore
Browse all →
